Beloranib
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury
Zafgen · Phase 2 · Completed · Enrollment 14
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| ZGN-440 sterile diluent | n/r | n/r | n/r | n/r |
| ZGN-440 for injectable suspension | n/r | n/r | n/r | n/r |
Not shown
- ZGN-440 sterile diluent: endpoint not reported
- ZGN-440 for injectable suspension: endpoint not reported